New hope for blood cancer patients: experimental drug targets resistant polycythemia vera

NCT ID NCT07232290

Recruiting now Disease control Sponsor: Chengdu Zenitar Biomedical Technology Co., Ltd Source: ClinicalTrials.gov ↗

First seen Nov 18, 2025 · Last updated May 19, 2026 · Updated 17 times

Summary

This study tests a new pill, flonoltinib maleate, in 60 adults with polycythemia vera (a blood disorder causing too many red blood cells) who have not responded to or cannot tolerate standard therapies. The goal is to see if the drug safely controls red blood cell levels without needing frequent blood removal procedures. The trial is in an early phase (2a) and will compare different doses.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for POLYCYTHEMIA VERA (PV) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences (IHCAMS)
RECRUITING

Tianjin, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

POLYCYTHEMIA VERA (PV)